nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.0371	0.102	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.0364	0.1	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.0213	0.0585	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.0209	0.0575	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—NR1I3—liver cancer	0.0191	0.0526	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR1H4—liver cancer	0.0154	0.0423	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR1I3—liver cancer	0.0151	0.0415	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—HNF4A—liver cancer	0.0133	0.0364	CbGpPWpGaD
Rifaximin—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.0129	0.0355	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.0116	0.0318	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—HNF4A—liver cancer	0.0105	0.0288	CbGpPWpGaD
Rifaximin—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00778	0.0214	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.00762	0.0209	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARA—liver cancer	0.00697	0.0191	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR1—liver cancer	0.00632	0.0173	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.0063	0.0173	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARG—liver cancer	0.00576	0.0158	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARA—liver cancer	0.00551	0.0151	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR1—liver cancer	0.00499	0.0137	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARG—liver cancer	0.00455	0.0125	CbGpPWpGaD
Rifaximin—Neutropenia—Sorafenib—liver cancer	0.00436	0.00688	CcSEcCtD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00429	0.0118	CbGpPWpGaD
Rifaximin—Generalised oedema—Doxorubicin—liver cancer	0.00428	0.00675	CcSEcCtD
Rifaximin—Weight decreased—Sorafenib—liver cancer	0.00422	0.00666	CcSEcCtD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00421	0.0116	CbGpPWpGaD
Rifaximin—Pneumonia—Sorafenib—liver cancer	0.00419	0.0066	CcSEcCtD
Rifaximin—Infestation NOS—Sorafenib—liver cancer	0.00416	0.00656	CcSEcCtD
Rifaximin—Infestation—Sorafenib—liver cancer	0.00416	0.00656	CcSEcCtD
Rifaximin—Epistaxis—Sorafenib—liver cancer	0.00393	0.00619	CcSEcCtD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00392	0.0108	CbGpPWpGaD
Rifaximin—Haemoglobin—Sorafenib—liver cancer	0.00376	0.00592	CcSEcCtD
Rifaximin—Haemorrhage—Sorafenib—liver cancer	0.00374	0.00589	CcSEcCtD
Rifaximin—Dermatitis atopic—Epirubicin—liver cancer	0.00371	0.00586	CcSEcCtD
Rifaximin—Urinary tract disorder—Sorafenib—liver cancer	0.00369	0.00582	CcSEcCtD
Rifaximin—Urethral disorder—Sorafenib—liver cancer	0.00366	0.00578	CcSEcCtD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.0036	0.00988	CbGpPWpGaD
Rifaximin—Tinnitus—Sorafenib—liver cancer	0.00348	0.00549	CcSEcCtD
Rifaximin—Flushing—Sorafenib—liver cancer	0.00347	0.00547	CcSEcCtD
Rifaximin—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00346	0.00951	CbGpPWpGaD
Rifaximin—Dermatitis atopic—Doxorubicin—liver cancer	0.00344	0.00542	CcSEcCtD
Rifaximin—Ageusia—Epirubicin—liver cancer	0.00339	0.00535	CcSEcCtD
Rifaximin—Angiopathy—Sorafenib—liver cancer	0.00339	0.00535	CcSEcCtD
Rifaximin—Mediastinal disorder—Sorafenib—liver cancer	0.00337	0.00531	CcSEcCtD
Rifaximin—Mental disorder—Sorafenib—liver cancer	0.00327	0.00516	CcSEcCtD
Rifaximin—Malnutrition—Sorafenib—liver cancer	0.00325	0.00513	CcSEcCtD
Rifaximin—Ageusia—Doxorubicin—liver cancer	0.00314	0.00495	CcSEcCtD
Rifaximin—Muscle spasms—Sorafenib—liver cancer	0.00313	0.00493	CcSEcCtD
Rifaximin—Bone disorder—Epirubicin—liver cancer	0.00304	0.0048	CcSEcCtD
Rifaximin—Cellulitis—Epirubicin—liver cancer	0.00302	0.00477	CcSEcCtD
Rifaximin—Anaemia—Sorafenib—liver cancer	0.00301	0.00474	CcSEcCtD
Rifaximin—Angioedema—Sorafenib—liver cancer	0.00297	0.00469	CcSEcCtD
Rifaximin—Syncope—Sorafenib—liver cancer	0.00292	0.0046	CcSEcCtD
Rifaximin—Loss of consciousness—Sorafenib—liver cancer	0.00286	0.00451	CcSEcCtD
Rifaximin—Cough—Sorafenib—liver cancer	0.00284	0.00448	CcSEcCtD
Rifaximin—Bone disorder—Doxorubicin—liver cancer	0.00282	0.00444	CcSEcCtD
Rifaximin—Cellulitis—Doxorubicin—liver cancer	0.0028	0.00441	CcSEcCtD
Rifaximin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00279	0.00766	CbGpPWpGaD
Rifaximin—Neck pain—Epirubicin—liver cancer	0.00278	0.00439	CcSEcCtD
Rifaximin—Myalgia—Sorafenib—liver cancer	0.00277	0.00437	CcSEcCtD
Rifaximin—Arthralgia—Sorafenib—liver cancer	0.00277	0.00437	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00275	0.00434	CcSEcCtD
Rifaximin—Abnormal dreams—Epirubicin—liver cancer	0.00272	0.00429	CcSEcCtD
Rifaximin—Dry mouth—Sorafenib—liver cancer	0.00271	0.00427	CcSEcCtD
Rifaximin—Hyperkalaemia—Epirubicin—liver cancer	0.0027	0.00426	CcSEcCtD
Rifaximin—Influenza like illness—Epirubicin—liver cancer	0.00267	0.00421	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—NR1H4—liver cancer	0.00266	0.0073	CbGpPWpGaD
Rifaximin—Anaphylactic shock—Sorafenib—liver cancer	0.00265	0.00419	CcSEcCtD
Rifaximin—Colitis—Epirubicin—liver cancer	0.00264	0.00416	CcSEcCtD
Rifaximin—Infection—Sorafenib—liver cancer	0.00264	0.00416	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—NR1I3—liver cancer	0.00261	0.00718	CbGpPWpGaD
Rifaximin—Shock—Sorafenib—liver cancer	0.00261	0.00412	CcSEcCtD
Rifaximin—Fluid retention—Epirubicin—liver cancer	0.00261	0.00412	CcSEcCtD
Rifaximin—Nervous system disorder—Sorafenib—liver cancer	0.0026	0.00411	CcSEcCtD
Rifaximin—Skin disorder—Sorafenib—liver cancer	0.00258	0.00407	CcSEcCtD
Rifaximin—Neck pain—Doxorubicin—liver cancer	0.00258	0.00406	CcSEcCtD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00254	0.00698	CbGpPWpGaD
Rifaximin—Anorexia—Sorafenib—liver cancer	0.00253	0.00399	CcSEcCtD
Rifaximin—Abnormal dreams—Doxorubicin—liver cancer	0.00251	0.00397	CcSEcCtD
Rifaximin—Hyperkalaemia—Doxorubicin—liver cancer	0.0025	0.00394	CcSEcCtD
Rifaximin—Influenza like illness—Doxorubicin—liver cancer	0.00247	0.0039	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00246	0.00676	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00245	0.00673	CbGpPWpGaD
Rifaximin—Colitis—Doxorubicin—liver cancer	0.00244	0.00385	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00242	0.00665	CbGpPWpGaD
Rifaximin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00242	0.00381	CcSEcCtD
Rifaximin—Fluid retention—Doxorubicin—liver cancer	0.00242	0.00381	CcSEcCtD
Rifaximin—Dyspnoea—Sorafenib—liver cancer	0.00237	0.00373	CcSEcCtD
Rifaximin—Decreased appetite—Sorafenib—liver cancer	0.00231	0.00364	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00229	0.00361	CcSEcCtD
Rifaximin—Fatigue—Sorafenib—liver cancer	0.00229	0.00361	CcSEcCtD
Rifaximin—Constipation—Sorafenib—liver cancer	0.00227	0.00358	CcSEcCtD
Rifaximin—Pain—Sorafenib—liver cancer	0.00227	0.00358	CcSEcCtD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00226	0.00622	CbGpPWpGaD
Rifaximin—Gastrointestinal pain—Sorafenib—liver cancer	0.00217	0.00342	CcSEcCtD
Rifaximin—Hot flush—Epirubicin—liver cancer	0.00213	0.00337	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Epirubicin—liver cancer	0.00212	0.00334	CcSEcCtD
Rifaximin—Menopausal symptoms—Epirubicin—liver cancer	0.00212	0.00334	CcSEcCtD
Rifaximin—Urticaria—Sorafenib—liver cancer	0.00211	0.00333	CcSEcCtD
Rifaximin—Abdominal pain—Sorafenib—liver cancer	0.0021	0.00331	CcSEcCtD
Rifaximin—Body temperature increased—Sorafenib—liver cancer	0.0021	0.00331	CcSEcCtD
Rifaximin—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00205	0.00563	CbGpPWpGaD
Rifaximin—Hypoglycaemia—Epirubicin—liver cancer	0.00205	0.00323	CcSEcCtD
Rifaximin—Hyponatraemia—Epirubicin—liver cancer	0.002	0.00316	CcSEcCtD
Rifaximin—Pain in extremity—Epirubicin—liver cancer	0.002	0.00315	CcSEcCtD
Rifaximin—Hot flush—Doxorubicin—liver cancer	0.00197	0.00311	CcSEcCtD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00197	0.00542	CbGpPWpGaD
Rifaximin—Migraine—Epirubicin—liver cancer	0.00196	0.0031	CcSEcCtD
Rifaximin—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00196	0.00539	CbGpPWpGaD
Rifaximin—Menopausal symptoms—Doxorubicin—liver cancer	0.00196	0.00309	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00196	0.00309	CcSEcCtD
Rifaximin—Hypersensitivity—Sorafenib—liver cancer	0.00196	0.00308	CcSEcCtD
Rifaximin—Asthenia—Sorafenib—liver cancer	0.0019	0.003	CcSEcCtD
Rifaximin—Hypoglycaemia—Doxorubicin—liver cancer	0.00189	0.00298	CcSEcCtD
Rifaximin—Pruritus—Sorafenib—liver cancer	0.00188	0.00296	CcSEcCtD
Rifaximin—Dehydration—Epirubicin—liver cancer	0.00186	0.00293	CcSEcCtD
Rifaximin—Hyponatraemia—Doxorubicin—liver cancer	0.00185	0.00292	CcSEcCtD
Rifaximin—Pain in extremity—Doxorubicin—liver cancer	0.00185	0.00291	CcSEcCtD
Rifaximin—Abdominal pain upper—Epirubicin—liver cancer	0.00182	0.00288	CcSEcCtD
Rifaximin—Migraine—Doxorubicin—liver cancer	0.00182	0.00287	CcSEcCtD
Rifaximin—Diarrhoea—Sorafenib—liver cancer	0.00182	0.00286	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—HNF4A—liver cancer	0.00181	0.00497	CbGpPWpGaD
Rifaximin—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.0018	0.00283	CcSEcCtD
Rifaximin—Nasopharyngitis—Epirubicin—liver cancer	0.00178	0.00282	CcSEcCtD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00176	0.00484	CbGpPWpGaD
Rifaximin—Rifampicin—CYP2E1—liver cancer	0.00176	1	CrCbGaD
Rifaximin—Dizziness—Sorafenib—liver cancer	0.00176	0.00277	CcSEcCtD
Rifaximin—Abdominal distension—Epirubicin—liver cancer	0.00174	0.00274	CcSEcCtD
Rifaximin—Dysphagia—Epirubicin—liver cancer	0.00173	0.00272	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—liver cancer	0.00172	0.00271	CcSEcCtD
Rifaximin—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.00169	0.00464	CbGpPWpGaD
Rifaximin—Vomiting—Sorafenib—liver cancer	0.00169	0.00266	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—liver cancer	0.00169	0.00266	CcSEcCtD
Rifaximin—Rash—Sorafenib—liver cancer	0.00167	0.00264	CcSEcCtD
Rifaximin—Dermatitis—Sorafenib—liver cancer	0.00167	0.00264	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00166	0.00262	CcSEcCtD
Rifaximin—Headache—Sorafenib—liver cancer	0.00166	0.00262	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—liver cancer	0.00165	0.0026	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—liver cancer	0.00161	0.00254	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—liver cancer	0.00161	0.00254	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—EXOSC2—liver cancer	0.00161	0.00442	CbGpPWpGaD
Rifaximin—Abdominal distension—Doxorubicin—liver cancer	0.00161	0.00253	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—liver cancer	0.0016	0.00253	CcSEcCtD
Rifaximin—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.0016	0.0044	CbGpPWpGaD
Rifaximin—Dysphagia—Doxorubicin—liver cancer	0.0016	0.00252	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—liver cancer	0.00159	0.00251	CcSEcCtD
Rifaximin—Nausea—Sorafenib—liver cancer	0.00158	0.00249	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—liver cancer	0.00157	0.00248	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—liver cancer	0.00157	0.00248	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00156	0.00429	CbGpPWpGaD
Rifaximin—Weight decreased—Epirubicin—liver cancer	0.00156	0.00246	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—liver cancer	0.00156	0.00245	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—liver cancer	0.00155	0.00244	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—liver cancer	0.00154	0.00243	CcSEcCtD
Rifaximin—Infestation—Epirubicin—liver cancer	0.00154	0.00243	CcSEcCtD
Rifaximin—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00154	0.00422	CbGpPWpGaD
Rifaximin—Dysuria—Doxorubicin—liver cancer	0.00149	0.00235	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—liver cancer	0.00149	0.00235	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00148	0.00234	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—liver cancer	0.00147	0.00233	CcSEcCtD
Rifaximin—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.00147	0.00405	CbGpPWpGaD
Rifaximin—Haematuria—Epirubicin—liver cancer	0.00147	0.00231	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—liver cancer	0.00146	0.0023	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—liver cancer	0.00145	0.00229	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—liver cancer	0.00145	0.00229	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—liver cancer	0.00144	0.00228	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—liver cancer	0.00144	0.00227	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—liver cancer	0.00143	0.00226	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—liver cancer	0.00142	0.00224	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—liver cancer	0.00142	0.00224	CcSEcCtD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.00142	0.00389	CbGpPWpGaD
Rifaximin—Haemoglobin—Epirubicin—liver cancer	0.00139	0.00219	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—liver cancer	0.00138	0.00218	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—liver cancer	0.00138	0.00218	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—liver cancer	0.00137	0.00217	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—liver cancer	0.00137	0.00216	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—liver cancer	0.00136	0.00215	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—liver cancer	0.00136	0.00215	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—liver cancer	0.00136	0.00214	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—liver cancer	0.00135	0.00213	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—liver cancer	0.00134	0.00212	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00134	0.00368	CbGpPWpGaD
Rifaximin—Tinnitus—Epirubicin—liver cancer	0.00129	0.00203	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—liver cancer	0.00128	0.00203	CcSEcCtD
Rifaximin—Flushing—Epirubicin—liver cancer	0.00128	0.00202	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—liver cancer	0.00128	0.00202	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NR1H4—liver cancer	0.00128	0.00351	CbGpPWpGaD
Rifaximin—Haemorrhage—Doxorubicin—liver cancer	0.00128	0.00202	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—liver cancer	0.00127	0.002	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—liver cancer	0.00127	0.002	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00127	0.00348	CbGpPWpGaD
Rifaximin—Urinary tract disorder—Doxorubicin—liver cancer	0.00126	0.00199	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—liver cancer	0.00126	0.00199	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NR1I3—liver cancer	0.00126	0.00346	CbGpPWpGaD
Rifaximin—Angiopathy—Epirubicin—liver cancer	0.00125	0.00198	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—liver cancer	0.00125	0.00198	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—liver cancer	0.00124	0.00196	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—liver cancer	0.00121	0.00191	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—liver cancer	0.0012	0.0019	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—liver cancer	0.00119	0.00188	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—liver cancer	0.00119	0.00187	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—liver cancer	0.00118	0.00187	CcSEcCtD
Rifaximin—Back pain—Epirubicin—liver cancer	0.00116	0.00183	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—liver cancer	0.00116	0.00183	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—liver cancer	0.00116	0.00182	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—UGDH—liver cancer	0.00115	0.00316	CbGpPWpGaD
Rifaximin—Mediastinal disorder—Doxorubicin—liver cancer	0.00115	0.00182	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—liver cancer	0.00112	0.00177	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—liver cancer	0.00112	0.00176	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—liver cancer	0.00111	0.00175	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—liver cancer	0.00111	0.00175	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—liver cancer	0.0011	0.00173	CcSEcCtD
Rifaximin—Malaise—Epirubicin—liver cancer	0.00108	0.00171	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—liver cancer	0.00108	0.0017	CcSEcCtD
Rifaximin—Syncope—Epirubicin—liver cancer	0.00108	0.0017	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—liver cancer	0.00108	0.0017	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—liver cancer	0.00107	0.00169	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—liver cancer	0.00106	0.00167	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.00105	0.00289	CbGpPWpGaD
Rifaximin—Cough—Epirubicin—liver cancer	0.00105	0.00165	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—liver cancer	0.00103	0.00163	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—liver cancer	0.00103	0.00162	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—liver cancer	0.00102	0.00161	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—liver cancer	0.00102	0.00161	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—liver cancer	0.00102	0.00161	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00102	0.0016	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—liver cancer	0.00101	0.00159	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—liver cancer	0.001	0.00158	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—liver cancer	0.001	0.00158	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—liver cancer	0.000999	0.00158	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—liver cancer	0.000997	0.00157	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—liver cancer	0.000989	0.00156	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—liver cancer	0.000981	0.00155	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—liver cancer	0.000978	0.00154	CcSEcCtD
Rifaximin—Infection—Epirubicin—liver cancer	0.000975	0.00154	CcSEcCtD
Rifaximin—Cough—Doxorubicin—liver cancer	0.000971	0.00153	CcSEcCtD
Rifaximin—Shock—Epirubicin—liver cancer	0.000965	0.00152	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—liver cancer	0.000962	0.00152	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—liver cancer	0.000953	0.0015	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARA—liver cancer	0.000952	0.00261	CbGpPWpGaD
Rifaximin—Hyperhidrosis—Epirubicin—liver cancer	0.000948	0.0015	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—liver cancer	0.000947	0.00149	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—liver cancer	0.000947	0.00149	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—liver cancer	0.000947	0.00149	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00094	0.00148	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—liver cancer	0.000936	0.00148	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—liver cancer	0.000935	0.00147	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—liver cancer	0.000926	0.00146	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—liver cancer	0.000917	0.00145	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—liver cancer	0.000915	0.00144	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—liver cancer	0.000908	0.00143	CcSEcCtD
Rifaximin—Infection—Doxorubicin—liver cancer	0.000902	0.00142	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000894	0.00141	CcSEcCtD
Rifaximin—Shock—Doxorubicin—liver cancer	0.000893	0.00141	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—liver cancer	0.00089	0.0014	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—liver cancer	0.000887	0.0014	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—liver cancer	0.000882	0.00139	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000881	0.00242	CbGpPWpGaD
Rifaximin—Hyperhidrosis—Doxorubicin—liver cancer	0.000878	0.00138	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—liver cancer	0.000875	0.00138	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—HNF4A—liver cancer	0.000872	0.00239	CbGpPWpGaD
Rifaximin—Anorexia—Doxorubicin—liver cancer	0.000865	0.00136	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—liver cancer	0.000862	0.00237	CbGpPWpGaD
Rifaximin—Decreased appetite—Epirubicin—liver cancer	0.000853	0.00135	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000852	0.00234	CbGpPWpGaD
Rifaximin—Hypotension—Doxorubicin—liver cancer	0.000848	0.00134	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—liver cancer	0.000847	0.00134	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—liver cancer	0.000846	0.00133	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00084	0.00231	CbGpPWpGaD
Rifaximin—Constipation—Epirubicin—liver cancer	0.000839	0.00132	CcSEcCtD
Rifaximin—Pain—Epirubicin—liver cancer	0.000839	0.00132	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000827	0.0013	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—liver cancer	0.000821	0.00129	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—liver cancer	0.000809	0.00128	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—liver cancer	0.000808	0.00128	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—liver cancer	0.000802	0.00127	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—liver cancer	0.000789	0.00124	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARG—liver cancer	0.000787	0.00216	CbGpPWpGaD
Rifaximin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000784	0.00124	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—liver cancer	0.000783	0.00123	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—liver cancer	0.000779	0.00123	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—liver cancer	0.000776	0.00122	CcSEcCtD
Rifaximin—Pain—Doxorubicin—liver cancer	0.000776	0.00122	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—liver cancer	0.000776	0.00122	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—liver cancer	0.000776	0.00122	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PSMD10—liver cancer	0.000762	0.00209	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PSMA4—liver cancer	0.000762	0.00209	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000757	0.00208	CbGpPWpGaD
Rifaximin—Feeling abnormal—Doxorubicin—liver cancer	0.000748	0.00118	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000742	0.00117	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000729	0.002	CbGpPWpGaD
Rifaximin—Hypersensitivity—Epirubicin—liver cancer	0.000723	0.00114	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—liver cancer	0.000721	0.00114	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—liver cancer	0.000718	0.00113	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—liver cancer	0.000718	0.00113	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—SERPINE1—liver cancer	0.000709	0.00195	CbGpPWpGaD
Rifaximin—Asthenia—Epirubicin—liver cancer	0.000704	0.00111	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—liver cancer	0.000694	0.00109	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00069	0.0019	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000673	0.00185	CbGpPWpGaD
Rifaximin—Diarrhoea—Epirubicin—liver cancer	0.000671	0.00106	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—liver cancer	0.000669	0.00105	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000662	0.00182	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000653	0.00179	CbGpPWpGaD
Rifaximin—Asthenia—Doxorubicin—liver cancer	0.000651	0.00103	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—liver cancer	0.000649	0.00102	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—liver cancer	0.000642	0.00101	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—liver cancer	0.000624	0.000984	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—liver cancer	0.000621	0.00098	CcSEcCtD
Rifaximin—Rash—Epirubicin—liver cancer	0.000619	0.000976	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—liver cancer	0.000618	0.000975	CcSEcCtD
Rifaximin—Headache—Epirubicin—liver cancer	0.000615	0.000969	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000612	0.00168	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000605	0.00166	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000604	0.00166	CbGpPWpGaD
Rifaximin—Dizziness—Doxorubicin—liver cancer	0.0006	0.000947	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000597	0.00164	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.00059	0.00162	CbGpPWpGaD
Rifaximin—Nausea—Epirubicin—liver cancer	0.000583	0.000919	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—liver cancer	0.000577	0.00091	CcSEcCtD
Rifaximin—Rash—Doxorubicin—liver cancer	0.000572	0.000903	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—liver cancer	0.000572	0.000902	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000569	0.00156	CbGpPWpGaD
Rifaximin—Headache—Doxorubicin—liver cancer	0.000569	0.000897	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000563	0.00155	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000555	0.00152	CbGpPWpGaD
Rifaximin—Nausea—Doxorubicin—liver cancer	0.000539	0.00085	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—H2AFX—liver cancer	0.000515	0.00141	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000496	0.00136	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000472	0.0013	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARA—liver cancer	0.000458	0.00126	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.00045	0.00124	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—liver cancer	0.000448	0.00123	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MAPK14—liver cancer	0.000423	0.00116	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR1—liver cancer	0.000415	0.00114	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARG—liver cancer	0.000379	0.00104	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000367	0.00101	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000362	0.000993	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SERPINE1—liver cancer	0.000341	0.000937	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000337	0.000924	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000302	0.00083	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000298	0.000819	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000278	0.000763	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000274	0.000753	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000263	0.000723	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.00026	0.000713	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—liver cancer	0.000216	0.000593	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UGDH—liver cancer	0.000197	0.000541	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—EPT1—liver cancer	0.000185	0.000509	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TAT—liver cancer	0.000176	0.000482	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—liver cancer	0.00015	0.000411	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CPT1B—liver cancer	0.000119	0.000328	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GLUL—liver cancer	0.000119	0.000328	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NR1H4—liver cancer	0.000115	0.000316	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA3—liver cancer	0.000113	0.000311	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA4—liver cancer	0.000104	0.000284	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA2—liver cancer	0.000101	0.000277	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA1—liver cancer	9.73e-05	0.000267	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAT2—liver cancer	9.62e-05	0.000264	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALDOB—liver cancer	9.23e-05	0.000253	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CRABP1—liver cancer	8.8e-05	0.000242	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HPGDS—liver cancer	7.69e-05	0.000211	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSMA4—liver cancer	6.86e-05	0.000188	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSMD10—liver cancer	6.86e-05	0.000188	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GOT2—liver cancer	6.67e-05	0.000183	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2E1—liver cancer	6.27e-05	0.000172	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYCS—liver cancer	5.87e-05	0.000161	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GOT1—liver cancer	5.76e-05	0.000158	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GGT1—liver cancer	5.76e-05	0.000158	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTP1—liver cancer	5.17e-05	0.000142	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMOX1—liver cancer	5.1e-05	0.00014	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—liver cancer	4.75e-05	0.000131	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1A1—liver cancer	4.51e-05	0.000124	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—liver cancer	4.2e-05	0.000115	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARA—liver cancer	4.12e-05	0.000113	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—liver cancer	3.53e-05	9.69e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARG—liver cancer	3.41e-05	9.35e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CD—liver cancer	3.1e-05	8.52e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—liver cancer	3.06e-05	8.41e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CB—liver cancer	2.7e-05	7.43e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CA—liver cancer	1.65e-05	4.53e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—liver cancer	1.35e-05	3.7e-05	CbGpPWpGaD
